Title:
METHOD FOR SCREENING COMPOUND SPECIFICALLY INHIBITING FORMATION OF CAVEOLAE IN CANCER CELLS, SCREENING KIT, VECTOR AND TRANSFORMANT TO BE USED IN KIT, AND METHOD FOR SELECTING PATIENT ADAPTABLE FOR MOLECULAR-TARGETING DRUG
Document Type and Number:
WIPO Patent Application WO/2016/063637
Kind Code:
A1
Abstract:
Provided is a method for screening a compound, said compound being capable of specifically inhibiting the formation of caveolae in cancer cells and comprehensively inhibiting various RTK activities only by the single compound.
A screening method that is the method for screening a compound capable of specifically inhibiting the formation of caveolae in cancer cells, said screening method being characterized by comprising a step for contacting test compounds with a system capable of detecting the inhibition of the binding of Cavin-1 and CAV1, and a step for selecting a compound having an activity of inhibiting the binding of Cavin-1 and CAV1.
Inventors:
TAKAHASHI TAKASHI (JP)
YAMAGUCHI TOMOYA (JP)
YAMAGUCHI TOMOYA (JP)
Application Number:
PCT/JP2015/075127
Publication Date:
April 28, 2016
Filing Date:
September 03, 2015
Export Citation:
Assignee:
UNIV NAGOYA NAT UNIV CORP (JP)
International Classes:
C12Q1/02; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/09; G01N33/15; G01N33/50; G01N33/68
Other References:
MASIAKOWSKI P. ET AL.: "A novel family of cell surface receptors with tyrosine kinase-like domain", J BIOL CHEM., vol. 267, no. 36, 1992, pages 26181 - 26190, XP002267720
AUNG CS . ET AL.: "PTRF-cavin-1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metalloprotease 9.", EUR J CELL BIOL., vol. 90, no. 2-3, 2011, pages 136 - 142, XP028129409
NASSAR ZD. ET AL.: "PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis.", ONCOTARGET, vol. 4, no. 10, 2013, pages 1844 - 1855, XP055275178
HIROSHI YANO: "Tokushu Kansaibo Gan no Vascular Invasion Bunshi Byorigakuteki Kento kara no Myakukan Shinjun Shindan", JOURNAL OF HEPATO- BILIARY-PANCREATIC SCIENCES, vol. 66, no. 6, 2013, pages 885 - 891, XP008185386
ZHA J. ET AL.: "Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.", MOL CANCER THER., vol. 8, no. 8, 2009, pages 2110 - 2121, XP055001421
LUDOVINI V. ET AL.: "High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small- cell lung cancer patient", ANN ONCOL., vol. 20, no. 5, 2009, pages 842 - 849, XP055275200
CAPPUZZO F. ET AL.: "Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small- cell lung cancer (NSCLC) patients.", ANN ONCOL., vol. 21, no. 3, 2010, pages 562 - 567, XP055275205
See also references of EP 3211087A4
AUNG CS . ET AL.: "PTRF-cavin-1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metalloprotease 9.", EUR J CELL BIOL., vol. 90, no. 2-3, 2011, pages 136 - 142, XP028129409
NASSAR ZD. ET AL.: "PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis.", ONCOTARGET, vol. 4, no. 10, 2013, pages 1844 - 1855, XP055275178
HIROSHI YANO: "Tokushu Kansaibo Gan no Vascular Invasion Bunshi Byorigakuteki Kento kara no Myakukan Shinjun Shindan", JOURNAL OF HEPATO- BILIARY-PANCREATIC SCIENCES, vol. 66, no. 6, 2013, pages 885 - 891, XP008185386
ZHA J. ET AL.: "Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer.", MOL CANCER THER., vol. 8, no. 8, 2009, pages 2110 - 2121, XP055001421
LUDOVINI V. ET AL.: "High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small- cell lung cancer patient", ANN ONCOL., vol. 20, no. 5, 2009, pages 842 - 849, XP055275200
CAPPUZZO F. ET AL.: "Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small- cell lung cancer (NSCLC) patients.", ANN ONCOL., vol. 21, no. 3, 2010, pages 562 - 567, XP055275205
See also references of EP 3211087A4
Attorney, Agent or Firm:
MATSUMOTO SEIJI (JP)
Seiji Matsumoto (JP)
Seiji Matsumoto (JP)
Download PDF:
Previous Patent: FLUORESCENCE OBSERVATION METHOD AND FLUORESCENCE OBSERVATION DEVICE
Next Patent: UNDERWEAR-TYPE DISPOSABLE DIAPER
Next Patent: UNDERWEAR-TYPE DISPOSABLE DIAPER